Neuropeptide Y receptor

From Wikipedia, the free encyclopedia
  (Redirected from NPY receptor)
Jump to: navigation, search
neuropeptide Y receptor Y1
Identifiers
Symbol NPY1R
Alt. symbols NPYR
Entrez 4886
HUGO 7956
OMIM 162641
RefSeq NM_000909
UniProt P25929
Other data
Locus Chr. 4 q31.3-q32
neuropeptide Y receptor Y2
Identifiers
Symbol NPY2R
Entrez 4887
HUGO 7957
OMIM 162642
RefSeq NM_000910
UniProt P49146
Other data
Locus Chr. 4 q31
pancreatic polypeptide receptor 1
Identifiers
Symbol PPYR1
Alt. symbols NPY4R, Y4, PP1
Entrez 5540
HUGO 9329
OMIM 601790
RefSeq NM_005972
UniProt P50391
Other data
Locus Chr. 10 q11.2
neuropeptide Y receptor Y5
Identifiers
Symbol NPY5R
Entrez 4889
HUGO 7958
OMIM 602001
RefSeq NM_006174
UniProt Q15761
Other data
Locus Chr. 4 q31-q32

Neuropeptide Y receptors are a class of G-protein coupled receptors which are activated by the closely related peptide hormones neuropeptide Y, peptide YY and pancreatic polypeptide.[1] These receptors are involved in the control of a diverse set of behavioral processes including appetite, circadian rhythm, and anxiety.[2][3][4][5][6][7]

Activated neuropeptide receptors release the Gi subunit from the heterotrimeric G protein complex. The Gi subunit in turn inhibits the production of the second messenger cAMP from ATP.

Types[edit]

There are five known mammalian neuropeptide Y receptors designated Y1 through Y5.[8] Four neuropeptide Y receptors each encoded by a different gene have been identified in humans, all of which may represent therapeutic targets for obesity and other disorders.[9][10][11]

Antagonists[edit]

References[edit]

  1. ^ Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (March 1998). "XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors". Pharmacol. Rev. 50 (1): 143–50. PMID 9549761. 
  2. ^ Heilig M (August 2004). "The NPY system in stress, anxiety and depression". Neuropeptides 38 (4): 213–24. doi:10.1016/j.npep.2004.05.002. PMID 15337373. 
  3. ^ Harro J (October 2006). "CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies". Amino Acids 31 (3): 215–30. doi:10.1007/s00726-006-0334-x. PMID 16738800. 
  4. ^ Eaton K, Sallee FR, Sah R (2007). "Relevance of neuropeptide Y (NPY) in psychiatry". Current Topics in Medicinal Chemistry 7 (17): 1645–59. doi:10.2174/156802607782341037. PMID 17979774. 
  5. ^ Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (November 2006). "Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide". Recent Patents on CNS Drug Discovery 1 (3): 315–24. doi:10.2174/157488906778773689. PMID 18221213. 
  6. ^ Vona-Davis LC, McFadden DW (2007). "NPY family of hormones: clinical relevance and potential use in gastrointestinal disease". Current Topics in Medicinal Chemistry 7 (17): 1710–20. doi:10.2174/156802607782340966. PMID 17979780. 
  7. ^ Lindner D, Stichel J, Beck-Sickinger AG (September 2008). "Molecular recognition of the NPY hormone family by their receptors". Nutrition (Burbank, Los Angeles County, Calif.) 24 (9): 907–17. doi:10.1016/j.nut.2008.06.025. PMID 18725086. 
  8. ^ Larhammar D, Salaneck E (2004). "Molecular evolution of NPY receptor subtypes". Neuropeptides 38 (4): 141–51. doi:10.1016/j.npep.2004.06.002. PMID 15337367. 
  9. ^ Kamiji MM, Inui A (October 2007). "Neuropeptide y receptor selective ligands in the treatment of obesity". Endocrine Reviews 28 (6): 664–84. doi:10.1210/er.2007-0003. PMID 17785427. 
  10. ^ MacNeil DJ (2007). "NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs". Current Topics in Medicinal Chemistry 7 (17): 1721–33. doi:10.2174/156802607782341028. PMID 17979781. 
  11. ^ Kamiji MM, Inui A (2007). "NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?". Current Topics in Medicinal Chemistry 7 (17): 1734–42. doi:10.2174/156802607782340957. PMID 17979782. 

External links[edit]